Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance

Pósa, Vivien and Stefanelli, Alessia and Bormio Nunes, Julia H. and Hager, Sonja and Mathuber, Marlene and May, Nóra Veronika and Enyedy, Éva Anna (2022) Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance. CANCERS, 14 (18). No. 4455. ISSN 2072-6694

Preview

Text cancers-14-04455-1.pdf Available under License Creative Commons Attribution. Download (3MB) | Preview

Abstract

COTI-2 is currently being evaluated in a phase I clinical trial for the treatment of gynecological and other solid cancers. As a thiosemicarbazone, this compound contains an N,N,S-chelating moiety and is, therefore, expected to bind endogenous metal ions. However, besides zinc, the metal interaction properties of COTI-2 have not been investigated in detail so far. This is unexpected, as we have recently shown that COTI-2 forms stable ternary complexes with copper and glutathione, which renders this drug a substrate for the resistance efflux transporter ABCC1. Herein, the complex formation of COTI-2, two novel terminal N-disubstituted derivatives (COTI-NMe2 and COTI-NMeCy), and the non-substituted analogue (COTI-NH2) with iron, copper, and zinc ions was characterized in detail. Furthermore, their activities against drug-resistant cancer cells was investigated in comparison to COTI-2 and Triapine. These data revealed that, besides zinc, also iron and copper ions need to be considered to play a role in the mode of action and resistance development of these thiosemicarbazones. Moreover, we identified COTI-NMe2 as an interesting new drug candidate with improved anticancer activity and resistance profile.

Actions (login required)

Edit Item